Shopping Cart
Remove All
Your shopping cart is currently empty
ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $37 | In Stock | In Stock | |
| 5 mg | $89 | In Stock | In Stock | |
| 10 mg | $163 | In Stock | In Stock | |
| 25 mg | $359 | In Stock | In Stock | |
| 50 mg | $562 | In Stock | In Stock | |
| 100 mg | $790 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF. |
| In vitro | ML228 introduces a new chemical class for researchers exploring HIF activation and its therapeutic applications. Unlike existing HIF activators, ML228's structure significantly diverges, notably absent of the acidic functional group typically found in PHD inhibitors—an attribute potentially crucial for specific disease contexts[1][2]. |
| In vivo | ML228 (injection; 1 µg/kg; 7 days) treatment following spinal cord injury (SCI) improves the local hypoxic-ischemic environment, reduces SCI secondary injury, and promotes neurological function recovery[3]. |
| Molecular Weight | 415.49 |
| Formula | C27H21N5 |
| Cas No. | 1357171-62-0 |
| Smiles | C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1 |
| Relative Density. | 1.228 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (132.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.